Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it will open a new office in San Diego, California, in June 2019.
The new office will be responsible for advancing product development, building a network, exploring new research seeds, and gathering technological information for the Regenerative Medicine/Cell Therapy Business in the U.S.
Upon opening, it will be staffed by several persons and operate as a branch office of our U.S. subsidiary Sunovion Pharmaceuticals Inc.
Hailed as one of the leading biotechnology clusters in the U.S., San Diego is home to numerous academic institutions and affiliated research laboratories, biotech venture businesses, and biopharmaceutical companies, making it an ideal base for product development, collaborative network building, and information gathering for the Regenerative Medicine/Cell Therapy Business.
Sumitomo Dainippon Pharma is working on six R&D projects for neurological disorders, eye diseases, and other serious medical conditions in the Regenerative Medicine/Cell Therapy fields, in collaboration with academic institutions and biotech venture businesses. With the establishment of this foothold in San Diego, Sumitomo Dainippon Pharma will pursue opportunities for advancing its Regenerative Medicine/Cell Therapy Business in the U.S., as well as in Japan.
(C) 2019 Electronic News Publishing, source ENP Newswire